65,437 trials
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline Computer-based Continuous Performance Test (cb- CPT; Qbtech AB, Sweden), Variable: Hyperactivity (Includes Time Active [TA], Distance [DIS], Area…
Migraine
Primary: Participants With Elimination of Nausea at 2 Hours Postdose — 130; 57; 55; 35 Participants
Multiple Sclerosis
Primary: Congestive Heart Failure (Treatment Phase) — 6 participants
Cryptococcal Meningitis
Primary: Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug — 2; 1; 0; 0 Events
Choroidal Neovascularization · Macular Degeneration
Primary: Mean Number of Retreatments (Day 0 Excluded) — 3.97; 3.00; 4.05; 5.39 number of retreatments
Non-Hodgkin's Lymphoma
Primary: Overall Response Rate — 17 pariticipants
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15 — 9.31; 9.31; -2.54; -1.66 Score on a scale — p=<0.001
Childhood-onset Growth Hormone Deficiency · Pituitary Dwarfism
Primary: Percent Change From Baseline to Week 24 in Trunk Fat — -6.27; -8.36 percent change — p=0.177
Pneumonia, Ventilator-Associated · Pneumonia, Bacterial · Pneumonia
Primary: Patients With Incidence of Treatment-emergent Adverse Events (TEAEs). — 42; 13; 37; 15 participants
Coronary Arteriosclerosis · Arteriosclerosis, Coronary · Atherosclerosis, Coronary
Primary: Mean Coronary Wall Thickness — 2.0 mm
Asthma
Primary: Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL) — 2.57; 0.87 pg/mL — p=0.011
Kennedy's Disease · Spinal and Bulbar Muscular Atrophy
Primary: Muscle Strength Change From Baseline — -2.2; 3.1; -4.5; 1.3 percent change — p=0.28
Bacterial Infections
Primary: Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 0 participants
Diabetic Neuropathy, Painful
Primary: Change From Baseline to Study Endpoint in Mean Weekly Pain Scores — -1.20; -1.82; -1.94 score on scale — p=0.0075
Ovarian Neoplasms
Primary: Occurrences of Infusion Reactions and Palmar-Plantar Erythrodysesthesia (PPE) — 2; 5; 2; 1 Events